戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  the Burch colposuspension--among women with stress incontinence.
2 cacious and an important therapy in managing stress incontinence.
3 le of these procedures in difficult cases of stress incontinence.
4 ce in women without preoperative symptoms of stress incontinence.
5  overactivity or sling procedures for female stress incontinence.
6 ge incontinence should be distinguished from stress incontinence.
7 secured its place in the treatment of female stress incontinence.
8 tinence but was not predictive in a study of stress incontinence.
9 nce continued incontinence despite "cure" of stress incontinence.
10 ed to quantify urine leakage associated with stress incontinence.
11 prehensive behavioral program for women with stress incontinence.
12 on (PFES) has been shown to be effective for stress incontinence.
13 nsobturator midurethral slings in women with stress incontinence.
14 neuromodulation, and surgical procedures for stress incontinence.
15 eficiency prior to surgical intervention for stress incontinence?
16 inence than those in the Burch group who had stress incontinence (24.5 percent vs. 6.1 percent, P<0.0
17 s. 38%, P=0.01) and the category specific to stress incontinence (66% vs. 49%, P<0.001).
18 al urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER n
19 acceptable accuracy for classifying urge and stress incontinence and may be appropriate for use in pr
20         Women who did not report symptoms of stress incontinence and who chose to undergo sacrocolpop
21 er trial involving women without symptoms of stress incontinence and with anterior prolapse (of stage
22  in a higher rate of successful treatment of stress incontinence but also greater morbidity than the
23 s are increasingly used for the treatment of stress incontinence, but there are limited data comparin
24 ency of all incontinence episodes (P<0.001), stress-incontinence episodes (P=0.009), and urge-inconti
25 p had a greater decrease in the frequency of stress-incontinence episodes (P=0.02), but not of urge-i
26                     As surgical treatment of stress incontinence evolves, thorough understanding of s
27                Surgical management of female stress incontinence has progressed rapidly over the past
28                      Reported cure rates for stress incontinence immediately after a course of perine
29 er of surgical procedures to correct urinary stress incontinence in the female have been described.
30 ecause of a significantly lower frequency of stress incontinence in the group that underwent the Burc
31 fective and safe method for treating urinary stress incontinence in women, and have delivered improve
32 ruction is a consequence of surgery to treat stress incontinence in women.
33 rventions are effective in the management of stress incontinence, including open retropubic colposusp
34 f obstructed, overactive bladder with hidden stress incontinence increases with degree of POP, and al
35 e contemporary surgical treatment of urinary stress incontinence is by suburethral sling; so this rev
36            There is no FDA-approved drug for stress incontinence or overflow incontinence.
37 controls met one or more of the criteria for stress incontinence (P<0.001).
38 radic reports of unexpectedly high recurrent stress incontinence rates with some biological slings ha
39 e of urethral bulking and oral medicines for stress incontinence remains low because of inconsistent
40 omen with urethral hypermobility and genuine stress incontinence seems clear.
41 hageal reflux disease, hypertension, urinary stress incontinence, sleep apnea, obesity hypoventilatio
42 ndition, and success in terms of measures of stress incontinence specifically, which required only th
43                                              Stress incontinence surgery, the midurethral sling, is a
44    The primary outcomes included measures of stress incontinence (symptoms, stress testing, or treatm
45 more likely to report bothersome symptoms of stress incontinence than those in the Burch group who ha
46                        For classification of stress incontinence, the sensitivity was 0.86 (CI, 0.79
47 us injectable materials for the treatment of stress incontinence, there is no clear data to establish
48         The anatomic structures that prevent stress incontinence, urinary incontinence during elevati
49                             In women without stress incontinence who are undergoing abdominal sacroco
50 bjectively assessed success of treatment for stress incontinence with the retropubic and transobturat
51 nificantly reduced postoperative symptoms of stress incontinence without increasing other lower urina
52 cedures are available for women with urinary stress incontinence, yet few randomized clinical trials